In some cancers, it has been shown that AHR activation can contribute to the upregulation of PD1 and PDL1 expression in immune cells, such as T lymphocytes and monocytes, leading to immune suppression and tumour immune evasion. This evidence concerns the gene AHR and neoplasm.